+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study



The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study



Schizophrenia Research 93(1-3): 109-116



Based on the evidence that lamotrigine added to clozapine in refractory schizophrenic patients has reported promising results, the present 24-week double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of lamotrigine add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of treatment-resistant schizophrenic patients receiving clozapine. After clinical and neurocognitive assessments patients were randomly allocated to receive, in a double-blind design, either up to 200 mg/day of lamotrigine or a placebo. A final sample of fifty-one patients completed the study. The results obtained indicate that lamotrigine added to stable clozapine treatment showed a beneficial effect on the negative, positive and general psychopathological symptomatology in a sample of treatment-resistant schizophrenic patients. Regarding cognitive functions, improvement was observed in some explored areas, such as attentional resistance to interference, verbal fluency and executive functioning. The findings provide evidence that lamotrigine augmentation of clozapine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant schizophrenia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 017357417

Download citation: RISBibTeXText

PMID: 17383857

DOI: 10.1016/j.schres.2007.02.009


Related references

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Primary Care Companion to the Journal of Clinical Psychiatry 10(3): 187-190, 2008

A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64(4): 403-407, 2003

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Journal of Psychopharmacology 26(11): 1456-1462, 2012

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. International Clinical Psychopharmacology 19(2): 71-76, 2004

Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. International Journal of Neuropsychopharmacology 17(2): 337-340, 2014

A randomized double blind placebo controlled crossover add on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Research 7(2): 136-145, 1990

Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia Research 127(1-3): 93-99, 2011

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Therapeutic Advances in Psychopharmacology 8(7): 185-197, 2018

A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. Journal of Clinical Psychiatry 72(10): 1405-1412, 2011

Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 20(5): 556-559, 2000

A placebo controlled double blind crossover trial of lamotrigine as add on therapy on seizure frequency and severity in patients with treatment resistant partial epilepsy. Epilepsia 32(Suppl. 3): 14, 1991

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Archives of General Psychiatry 36(6): 657-664, 1979

Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. International Clinical Psychopharmacology 10(2): 67-72, 1995

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. Journal of Neurology Neurosurgery and Psychiatry 56(5): 448-453, 1993

Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalized epilepsy. Epilepsia 39(12): 1329-1333, 1998